Stryker Corporation $SYK Stock Holdings Lessened by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 2.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 255,838 shares of the medical technology company’s stock after selling 6,035 shares during the quarter. New York State Teachers Retirement System’s holdings in Stryker were worth $89,919,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the 3rd quarter valued at $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker in the third quarter worth $30,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker during the third quarter worth $34,000. Copia Wealth Management grew its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in Stryker in the fourth quarter valued at about $40,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Management kept FY?2026 guidance intact — organic sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, signaling confidence in medium?term demand and execution. Stryker maintains 2026 outlook
• Positive Sentiment: Cash flow and GAAP net income showed strength (operating cash from ops surged year?over?year; reported profit rose to $745M), providing balance?sheet flexibility. Q1 results: cash flow & net income up
• Positive Sentiment: Company says it has largely recovered operationally from the cyber incident, which management says disrupted the quarter but is being contained. That supports the decision to keep guidance. Stryker reports first quarter 2026 operating results
• Neutral Sentiment: Full Q1 press conference transcript and management commentary are available for details on recovery timing, regional trends and product?line performance — useful for assessing forward visibility. Q1 2026 press conference transcript
• Negative Sentiment: Q1 adjusted EPS of $2.60 missed the consensus (~$2.98) and revenue of $6.02B fell short of estimates (~$6.34B), a headline miss that pressured the stock. Q1 earnings snapshot / consensus miss
• Negative Sentiment: Management cited softer demand for implants and complex?procedure devices (orthopaedics, spine) and adjusted operating margin contraction (~180 bps), suggesting near?term revenue headwinds even as recovery from the cyber event continues. Reuters: misses estimates on muted demand

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research reports. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. BTIG Research reaffirmed a “buy” rating and set a $397.00 price objective on shares of Stryker in a research report on Tuesday, April 14th. Robert W. Baird set a $437.00 target price on shares of Stryker in a research note on Friday, January 30th. William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Finally, Needham & Company LLC increased their price target on shares of Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $421.11.

Stryker Stock Performance

Shares of NYSE SYK opened at $314.64 on Friday. The business’s 50-day simple moving average is $345.67 and its 200-day simple moving average is $356.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a 52 week low of $311.31 and a 52 week high of $404.87. The firm has a market cap of $120.50 billion, a price-to-earnings ratio of 37.46, a P/E/G ratio of 1.84 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 14.91 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Tuesday, March 31st. Stryker’s payout ratio is presently 41.90%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.